Bioinformatics-Driven Discovery of Aβ-Targeted Therapeutics and Diagnostic Biomarkers for Alzheimer's Disease.
Three small molecules, resveratrol, curcumin, and apigenin, demonstrated strong binding affinities for NFKBIA, clarifying the priority candidate gene and feasible strategic directions, which are expected to be translated into practical pathways for precision diagnosis and treatment of AD.